Search

Read about a medical student treated at MSK for aggressive cervical cancer who later returned to train alongside MSK surgeons.

… Friday, January 17, 2025 Anh Le had begun her second year of medical school in Chicago, in 2018, when she suddenly faced her own health emergency: a rare, deadly form of cervical cancer called glassy cell carcinoma. The diagnosis threw her life — and promising career — into turmoil. It also set her on

Learn about how first-year student get oriented to the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK).

… Friday, September 10, 2021 Whether you’re in grade school or graduate school, late summer means it’s back to school season. It comes with the anticipation of exciting opportunities to set new goals, learn new things, and meet new people. This is not lost on the 18 first-year students who recently began

SKI Director, Joan Massagué, PhD, is an internationally renowned cancer biologist and leading researcher in the study of cancer metastasis. He is featured in the July 29 MSK Science Spotlight.

… Wednesday, July 29, 2020 SKI Director, Joan Massagué, PhD , is an internationally renowned cancer biologist and leading researcher in the study of cancer metastasis, the cause of 90 percent of cancer deaths. He is featured in the July 29 MSK Science Spotlight . Dr. Massagué studies the control of stem

A team of researchers led by Memorial Sloan Kettering physician-scientist Charles L. Sawyers has reported on the preclinical development and early results from the first clinical trial of a promising new drug for prostate cancer.

… Wednesday, July 1, 2009 Summary A team of researchers led by Memorial Sloan Kettering physician-scientist Charles L. Sawyers has reported on the preclinical development and early results from the first clinical trial of a promising new drug for prostate cancer. A team of researchers led by Memorial Sloan

Learn how advanced basal cell carcinoma can be treated with a new combination radiation and drug therapy.

… Thursday, April 18, 2024 Millions of Americans develop basal cell carcinoma basal cell carcinoma (BCC) on their skin, usually on their face, neck, or head. It’s the most common form of skin cancer skin cancer and is rarely fatal, but it can be uncomfortable and unsightly. BCC can usually be removed with

One of MSK’s leading immunologists turned 60 on Friday, and scientists came to celebrate.

… Monday, September 12, 2016 Alexander (Sasha) Rudensky with former students and colleagues Sasha Rudensky (center left) with former students and colleagues Greg Barton (left), Jason Fontenot (center right), and Nicholas Arpaia (right). Dr. Rudensky with Dr. Barton of the University of California, Berkeley

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with relapsed or refractory non-Hodgkin lymphomas, profound immune suppression, and predicting the likelihood of treatment failure.

… Tuesday, April 1, 2025 While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune suppression and predicting the likelihood of treatment failure remain significant

MSK nanotechnology researchers have developed an innovative approach for measuring the permeability of living tumors.

… Tuesday, February 23, 2016 Summary Tumor permeability can be a critical factor in how well a cancer therapy works. MSK researchers developed a method to measure this by creating living tumor spheroids and infiltrating them with very small carbon nanotubes that give off infrared light. The more light

Learn more about how MSK is helping a new generation of patients — including triathlete Derrick Edwin — to navigate work and careers while undergoing treatment for cancer.

… Thursday, April 10, 2025 One November morning in 2021, Derrick Edwin woke with pain in his side — as a triathlete in peak condition, he knew something was off. “Two months before, I had completed an Ironman — that’s a 2.4-mile swim, 112 miles on the bike, followed by a full marathon — and I felt great

Obtenga más información sobre cómo MSK está ayudando a una nueva generación de pacientes, entre ellos el triatleta Derrick Edwin, a gestionar el trabajo y la carrera profesional y el tratamiento contra el cáncer.

… Thursday, April 10, 2025 Una mañana de noviembre de 2021, Derrick Edwin se despertó con dolor en un costado. Como triatleta en óptimas condiciones, sabía que algo andaba mal. “Dos meses antes, había completado un Ironman, eso implica 2.4 millas de natación, 112 millas en bicicleta, seguidas de un maratón